The significance of immunohistochemistry in the diagnosis and therapy of neoplasms

This review article details the diagnostical significance of immunohistochemistry, which has developed during the last quarter of the century. Certainly, the advancement of monoclonal antibody technology has been of great significance in assuring the place of immunohistochemistry in the modern accurate microscopic diagnosis of human neoplasms, as a method of choice in histopathology. The fact still remains that in order to properly assess any immunohistochemical reactivity used for differential diagnostic purposes, the target cells have to be identified as neoplastically transformed cells by routine histopathological techniques. Selected groups of target molecules of great significance in cancer biology are discussed. The discovery of neoplasm-associated antigens has not only made the more accurate diagnosis of human cancer feasible but has also shed light on the extensive immunophenotypical heterogeneity of even the most closely linked human malignancies. The identification of disseminated neoplastically transformed cells by immunohistochemistry has allowed for a clearer picture of cancer invasion and metastasis, as well as the evolution of the tumour cell associated immunophenotype towards increased malignancy. Some possibilities of neoplasm-associated antigen targeted, receptor-directed immunotherapy are discussed and reviewed in this manuscript. Future antineoplastic therapeutical approaches should see the inclusion of a variety of immunotherapies, in the form of an individualised ‘cocktail’ specific for the particular immunophenotypical pattern associated with each individual patient’s neoplastic disease.

[1]  G. Plowman,et al.  Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. Callahan p53 mutations, another breast cancer prognostic factor. , 1992, Journal of the National Cancer Institute.

[3]  H. Hsu,et al.  Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. , 1993, Cancer research.

[4]  J. Wands,et al.  p53 mutation in hepatocellular carcinoma after aflatoxin exposure , 1991, The Lancet.

[5]  S. Thibodeau,et al.  DNA mismatch repair genes hMLH1, hMSH2, and hMSH6 are not inactivated in bronchioloalveolar carcinomas of the lung , 2001, Cancer.

[6]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[7]  J. Folkman,et al.  Angiogenic factors. , 1987, Science.

[8]  M. Kraus,et al.  Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[9]  H. Höfler,et al.  Differentiation and proliferation patterns in human trophoblast revealed by c-erbB-2 oncogene product and EGF-R. , 1993, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[10]  J. Yokota,et al.  p53 mutations in human lung tumors. , 1992, Cancer research.

[11]  D. Altman,et al.  An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. , 1988, British Journal of Cancer.

[12]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[13]  L. Beex,et al.  Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study , 2004, Breast Cancer Research and Treatment.

[14]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[15]  R. Zinkernagel,et al.  Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo. , 1996, Journal of immunology.

[16]  Y. Yarden,et al.  Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. , 1990, Biochemistry.

[17]  J. Folkman New perspectives in clinical oncology from angiogenesis research. , 1996, European journal of cancer.

[18]  W. Bellamy Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. , 2001, Seminars in oncology.

[19]  J. Massagué,et al.  Transforming growth factor-beta. , 1992, Cancer surveys.

[20]  D. English,et al.  Prognostic significance of p53 over‐expression in thin melanomas , 1995, Melanoma research.

[21]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[22]  W. Gullick,et al.  Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. , 1991, British medical bulletin.

[23]  I. Screpanti,et al.  Epidermal growth factor promotes a neural phenotype in thymic epithelial cells and enhances neuropoietic cytokine expression , 1995, The Journal of cell biology.

[24]  A. Chinnaiyan,et al.  ICE-LAP6, a Novel Member of the ICE/Ced-3 Gene Family, Is Activated by the Cytotoxic T Cell Protease Granzyme B* , 1996, The Journal of Biological Chemistry.

[25]  G. Todaro,et al.  Human transforming growth factor. Production by a melanoma cell line, purification, and initial characterization. , 1982, The Journal of biological chemistry.

[26]  J. Moul,et al.  Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. , 1993, The Journal of urology.

[27]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[28]  J. Butel,et al.  Tumor suppressor p53 mutations and breast cancer: a critical analysis. , 1995, Advances in cancer research.

[29]  D. Green,et al.  Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. , 1992, Science.

[30]  M. O'reilly,et al.  A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. , 1997, Cancer research.

[31]  B. Bodey,et al.  Immunohistochemical detection of p53 protein overexpression in primary human osteosarcomas. , 1997, Anticancer research.

[32]  J. Folkman,et al.  Fighting cancer by attacking its blood supply. , 1996, Scientific American.

[33]  G. Plowman,et al.  Heregulin induces tyrosine phosphorylation of HER4/p180erbB4 , 1993, Nature.

[34]  J. Minna,et al.  p53: a frequent target for genetic abnormalities in lung cancer. , 1989, Science.

[35]  M. Ridanpää,et al.  p53 and ras Gene Mutations in Lung Cancer: Implications for Smoking and Occupational Exposures , 1995, Journal of occupational and environmental medicine.

[36]  M. Prados,et al.  Constitutional p53 mutations associated with brain tumors in young adults. , 1995, Cancer genetics and cytogenetics.

[37]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[38]  V. Wang,et al.  Microsatellite Instability, Expression of hMSH2 and hMLH1 and HPV Infection in Cervical Cancer and Their Clinico-Pathological Association , 2001, Gynecologic and Obstetric Investigation.

[39]  J. Folkman Addressing tumor blood vessels , 1997, Nature Biotechnology.

[40]  A. Levine,et al.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life , 1988, Molecular and cellular biology.

[41]  A. Ullrich,et al.  Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.

[42]  D. Meek,et al.  The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase II. , 1990, The EMBO journal.

[43]  J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[44]  C. Quinn,et al.  c‐erbB‐3 protein expression in human breast cancer: comparison with other tumour variables and survival , 1994, Histopathology.

[45]  G. Fischbach,et al.  Differential expression of ARIA isoforms in the rat brain , 1995, Neuron.

[46]  G. Hortobagyi,et al.  c-erbB-2 amplification in node-negative human breast cancer. , 1989, Cancer research.

[47]  R. Dittadi,et al.  Epidermal growth factor receptor in breast cancer. Comparison with non malignant breast tissue. , 1993, British Journal of Cancer.

[48]  D. Ellison,et al.  Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[49]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[50]  N. Lemoine,et al.  Expression of the c‐erbB‐3 gene product in gastric cancer , 1993, International journal of cancer.

[51]  M. Kawakami,et al.  Angiogenesis in pancreatic carcinoma , 2001, Cancer.

[52]  K. Kinzler,et al.  Identification of p53 as a sequence-specific DNA-binding protein , 1991, Science.

[53]  C. Croce,et al.  Bcl2 is the guardian of microtubule integrity. , 1997, Cancer research.

[54]  J. Jiricny,et al.  Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system. , 2002, Gastroenterology.

[55]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[56]  J. Folkman,et al.  Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[57]  J. Folkman Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[58]  R. D'Amato,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[59]  J. Cohen,et al.  Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. , 1984, Journal of immunology.

[60]  W. Reinhold,et al.  Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. , 1993, The Journal of clinical investigation.

[61]  E. Cundari,et al.  Deregulated apoptosis is a hallmark of the Fanconi anemia syndrome. , 1997, Cancer research.

[62]  W. Maltzman,et al.  UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells , 1984, Molecular and cellular biology.

[63]  M. Demeure,et al.  The clinical significance of micrometastases and molecular metastases. , 2001, Surgery.

[64]  D. Green,et al.  Dicing with death: dissecting the components of the apoptosis machinery. , 1994, Trends in biochemical sciences.

[65]  S. Cha,et al.  HER-2/neu expression: A major prognostic factor in endometrial cancer , 1992 .

[66]  C. Osborne,et al.  HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Dario Neri,et al.  Targeting by affinity–matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform , 1997, Nature Biotechnology.

[68]  J. Luck,et al.  Immunocytochemical detection of the p170 multidrug resistance (MDR) and the p53 tumor suppressor gene proteins in human breast cancer cells: clinical and therapeutical significance. , 1997, Anticancer research.

[69]  C. Haslett,et al.  Phagocyte recognition of cells undergoing apoptosis. , 1993, Immunology today.

[70]  J. Yokota,et al.  DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation. , 1997, Cancer research.

[71]  L. Owen-Schaub,et al.  DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. , 1992, Cellular immunology.

[72]  G. Niehans,et al.  Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. , 1994, Human pathology.

[73]  Mei Lan Tan,et al.  Apoptosis and Cancer , 2020, Cancer Immunology.

[74]  Rüdiger Klein,et al.  Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor , 1995, Nature.

[75]  M. Rifkin,et al.  Contribution of HER‐2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis , 1993, Cancer.

[76]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[77]  V. Gorgoulis,et al.  p53 gene alterations in special types of breast carcinoma: A molecular and immunohistochemical study in archival material , 1995, The Journal of pathology.

[78]  B. Gusterson,et al.  c-erbB-2 expression in benign and malignant breast disease. , 1988, British Journal of Cancer.

[79]  M. Cleary,et al.  Bcl2 inhibits apoptosis associated with terminal differentiation of HL-60 myeloid leukemia cells. , 1994, Blood.

[80]  Michael J. Fry,et al.  Phosphatidylinositol-3-OH kinase direct target of Ras , 1994, Nature.

[81]  J. Ross,et al.  The HER-2/neu Oncogene in Tumors of the Gastrointestinal Tract , 2001, Cancer investigation.

[82]  L. Mettler,et al.  Amplification of c-myc but not of c-erbB-2 is associated with high proliferative capacity in breast cancer. , 1993, Cancer research.

[83]  M. Hengartner,et al.  Caenorhabditis elegans gene ced-9 protects cells from programmed cell death , 1992, Nature.

[84]  L. Skoog,et al.  Receptors for epidermal growth factor and estrogen as predictors of relapse in patients with mammary carcinoma. , 1988, Anticancer research.

[85]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[86]  D. Schaid,et al.  Erratum: Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value (Proceedings of the National Academy of Science of the USA (February 6, 1996) 93 (1093-1096)) , 1996 .

[87]  R. Eisenberg,et al.  Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. , 1991, Annual review of immunology.

[88]  K. Plate,et al.  Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible In vivo regulatory mechanisms , 1994, International journal of cancer.

[89]  D. Taverna,et al.  Oestrogen and epidermal growth factor down-regulate erbB-2 oncogene protein expression in breast cancer cells by different mechanisms. , 1994, British Journal of Cancer.

[90]  A. Wellstein,et al.  Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors. , 1994, The Journal of biological chemistry.

[91]  M. Kraus,et al.  Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. , 1995, Oncogene.

[92]  P. Ravdin,et al.  The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review. , 1995, Gene.

[93]  A. Harris,et al.  Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  D. Eccles,et al.  p53 polymorphism in ovarian and breast cancer , 1996, The Lancet.

[95]  J. Little,et al.  Relationship between radiation-induced G1 phase arrest and p53 function in human tumor cells. , 1995, Cancer research.

[96]  J. Luck,et al.  Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. , 1997, Anticancer research.

[97]  B. Bodey,et al.  Immunophenotypically varied cell subpopulations in primary and metastatic human melanomas. Monoclonal antibodies for diagnosis, detection of neoplastic progression and receptor directed immunotherapy. , 1996, Anticancer research.

[98]  S. Nagata,et al.  Selective apoptosis of CD4+CD8+ thymocytes by the anti-Fas antibody , 1995, The Journal of experimental medicine.

[99]  P. O’Connell,et al.  Biomarkers in early breast neoplasia , 1993, Journal of cellular biochemistry. Supplement.

[100]  L. Ellis,et al.  The implications of angiogenesis for the biology and therapy of cancer metastasis , 1994, Cell.

[101]  J. Mankovich,et al.  Identification and Characterization of ICH-2, a Novel Member of the Interleukin-1β-converting Enzyme Family of Cysteine Proteases (*) , 1995, The Journal of Biological Chemistry.

[102]  Zhiwei Hu,et al.  Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[103]  Patrick R. Griffin,et al.  Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis , 1995, Nature.

[104]  Junying Yuan,et al.  Human ICE/CED-3 Protease Nomenclature , 1996, Cell.

[105]  F. Cavalli,et al.  Role of angiogenesis inhibitors in acute myeloid leukemia. , 2001, Cancer journal.

[106]  H. Gregory Isolation and structure of urogastrone and its relationship to epidermal growth factor , 1975, Nature.

[107]  E. Hudson,et al.  Met and hepatocyte growth factor/scatter factor expression in human gliomas. , 1997, Cancer research.

[108]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[109]  M. Press,et al.  Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. , 1995, Cancer research.

[110]  M. Stratton,et al.  Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours: molecular and immunohistochemical findings. , 1993, Oncogene.

[111]  I. Ellis,et al.  Pathological validation and significance of micrometastasis in sentinel nodes in primary breast cancer , 2001, Breast Cancer Research.

[112]  J. Marx New link found between p53 and DNA repair. , 1994, Science.

[113]  T. Shono,et al.  Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. , 1995, Cancer research.

[114]  J. Folkman,et al.  Angiogenesis and angiogenesis inhibition: an overview. , 1997, EXS.

[115]  B. Bodey,et al.  Fas (Apo-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells? , 1999, In vivo.

[116]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[117]  D. Scheinberg,et al.  Tumor Therapy with Targeted Atomic Nanogenerators , 2001, Science.

[118]  R. Kuwano,et al.  Expression of vascular endothelial growth factor in capillary hemangioblastoma. , 1993, Biochemical and biophysical research communications.

[119]  S. Hetts To die or not to die: an overview of apoptosis and its role in disease. , 1998, JAMA.

[120]  Terry Farrah,et al.  The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death , 1994, Cell.

[121]  C. Péchoux,et al.  Immunohistochemical studies on c-erbB-2 oncoprotein expression in paraffin embedded tissues in invasive and non-invasive human breast lesions. , 1994, Anticancer research.

[122]  H. Steller Mechanisms and genes of cellular suicide , 1995, Science.

[123]  A. Burgess,et al.  Structure-Function relationships for the EGF/TGF-α family of mitogens , 1994 .

[124]  W. Dougall,et al.  The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. , 1994, Oncogene.

[125]  A. Howell,et al.  C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis. , 1990, British Journal of Cancer.

[126]  H. Horvitz,et al.  The Caenorhabditis elegans genes ced-3 and ced-4 act cell autonomously to cause programmed cell death. , 1990, Developmental biology.

[127]  W. Cavenee,et al.  Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[128]  S. Ménard,et al.  Prognostic significance of her‐2/neu expression in breast cancer and its relationship to other prognostic factors , 1991, International journal of cancer.

[129]  W. Risau Differentiation of endothelium , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[130]  A. V. Koudrine Trace elements and apoptosis. , 1998, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements.

[131]  M. Fernö,et al.  ERBB2 amplification in breast cancer with a high rate of proliferation. , 1991, Oncogene.

[132]  T. Jacks,et al.  DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2 , 1994, Cell.

[133]  J. Winstanley,et al.  The long term prognostic significance of c-erbB-2 in primary breast cancer. , 1991, British Journal of Cancer.

[134]  M. Henderson,et al.  Comparison of EGFR, c-erbB-2 product and ras p21 immunohistochemistry as prognostic markers in primary breast cancer. , 1991, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[135]  M. Greene,et al.  The neu (c-erbB-2) oncogene. , 1989, Seminars in oncology.

[136]  John Calvin Reed Bcl-2 and the regulation of programmed cell death , 1994, The Journal of cell biology.

[137]  J. Healey,et al.  Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[138]  C. S. Lee,et al.  p53 in cutaneous melanoma: Immunoreactivity and correlation with prognosis , 1995, The Australasian journal of dermatology.

[139]  K. Müller,et al.  p53 tumour-suppressor gene in non-small-cell lung cancer with neoadjuvant therapy , 2000, Journal of Cancer Research and Clinical Oncology.

[140]  A. Sahin Biologic and Clinical Significance of HER‐2/neu (cerbB‐2) in Breast Cancer , 2000, Advances in anatomic pathology.

[141]  S. Cha,et al.  HER‐2/neu expression: A major prognostic factor in endometrial cancer , 1992, Gynecologic oncology.

[142]  R. Bergman,et al.  Immunohistochemical Study of p53 Protein Expression in Spitz Nevus as Compared with Other Melanocytic Lesions , 1995, The American Journal of dermatopathology.

[143]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[144]  D. Delia,et al.  In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11 , 1997, Anti-cancer drugs.

[145]  Jung Weon Shim,et al.  Expression of bFGF and VEGF in brain astrocytoma. , 1996, Journal of Korean medical science.

[146]  A. Harris,et al.  Increased expression of mutant forms of p53 oncogene in primary lung cancer , 1990, The Lancet.

[147]  C. A. Carraway,et al.  Signaling, mitogenesis and the cytoskeleton: where the action is. , 1995, BioEssays : news and reviews in molecular, cellular and developmental biology.

[148]  K. Dameron,et al.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. , 1994, Science.

[149]  G. Gaidano,et al.  p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[150]  P. Desnuelle,et al.  Molecular and cellular basis of digestion , 1986 .

[151]  I. Damjanov,et al.  Immunohistochemical localization of the epidermal growth factor receptor in normal human tissues. , 1986, Laboratory investigation; a journal of technical methods and pathology.

[152]  E. Kohn,et al.  The biochemistry of cancer dissemination. , 1997, Critical reviews in biochemistry and molecular biology.

[153]  T. Sekiya,et al.  Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. , 1996, Cancer research.

[154]  D. Zagzag Angiogenic growth factors in neural embryogenesis and neoplasia. , 1995, The American journal of pathology.

[155]  N. Colburn,et al.  Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor-suppressor gene isolated from nasopharyngeal carcinoma. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[156]  R. Dahiya,et al.  DNA mismatch repair enzyme activity and gene expression in prostate cancer. , 2001, Biochemical and biophysical research communications.

[157]  J. Bártková,et al.  The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. , 1991, British Journal of Cancer.

[158]  J. Gamble,et al.  Angiogenesis: models and modulators. , 1995, International review of cytology.

[159]  L. Zardi,et al.  A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors , 1989, The Journal of cell biology.

[160]  B. Karlan,et al.  HER‐2/neu, p53, and DNA Analyses as Prognosticators for Survival in Endometrial Carcinoma , 1995, Obstetrics and gynecology.

[161]  S. Nagata,et al.  Fas and Fas ligand: a death factor and its receptor. , 1994, Advances in immunology.

[162]  D. Louis,et al.  Histopathologic and immunohistochemical prognostic factors in malignant gliomas. , 1997, Current opinion in oncology.

[163]  B. Glickman,et al.  Sequence specificity of mutations induced by benzo[a]pyrene-7,8-diol-9,10-epoxide at endogenousaprt gene in CHO cells , 1988, Somatic cell and molecular genetics.

[164]  I. Ellis,et al.  c-erbB-2 oncoprotein expression in primary and advanced breast cancer. , 1991, British Journal of Cancer.

[165]  J. Silver,et al.  Differential expression of the human Thy-1 gene in rodent-human somatic cell hybrids [corrected]. , 1987, Journal of immunology.

[166]  E. White,et al.  Life, death, and the pursuit of apoptosis. , 1996, Genes & development.

[167]  David Wallach,et al.  Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor–Induced Cell Death , 1996, Cell.

[168]  E. Alnemri,et al.  CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. , 1994, The Journal of biological chemistry.

[169]  A. Paller,et al.  Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. , 1997, Cancer research.

[170]  James T. Elder,et al.  Overexpression of transforming growth factor alpha in psoriatic epidermis. , 1989, Science.

[171]  W. Risau What, if anything, is an angiogenic factor? , 1996, Cancer and Metastasis Reviews.

[172]  B. Vogelstein,et al.  Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication , 1991, Cell.

[173]  Lianfa Shi,et al.  Premature p34cdc2 activation required for apoptosis. , 1994, Science.

[174]  G. Wood,et al.  Alterations of Mismatch Repair Protein Expression in Benign Melanocytic Nevi, Melanocytic Dysplastic Nevi, and Cutaneous Malignant Melanomas , 2001, The American Journal of dermatopathology.

[175]  S. Nagata,et al.  The Fas death factor , 1995, Science.

[176]  A. Wellstein,et al.  A secreted FGF-binding protein can serve as the angiogenic switch in human cancer , 1997, Nature Medicine.

[177]  L. Wang,et al.  Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death , 1994, Cell.

[178]  J G Klijn,et al.  The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. , 1992, Endocrine reviews.

[179]  W. Clark,et al.  Biology of tumor progression in human melanocytes. , 1987, Laboratory investigation; a journal of technical methods and pathology.

[180]  A. von Deimling,et al.  Expression and distribution of vascular endothelial growth factor protein in human brain tumors , 1997, Acta Neuropathologica.

[181]  T. Mattfeldt,et al.  Expression of epidermal growth factor receptor in benign and malignant primary tumours of the breast , 2004, Virchows Archiv A.

[182]  N. Copeland,et al.  Induction of apoptosis by the mouse Nedd2 gene, which encodes a protein similar to the product of the Caenorhabditis elegans cell death gene ced-3 and the mammalian IL-1 beta-converting enzyme. , 1994, Genes & development.

[183]  M. N. Epstein,et al.  A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. , 1984, Human pathology.

[184]  J. Weatherill,et al.  c-erbB-3 protein expression in ovarian tumours. , 1995, British Journal of Cancer.

[185]  R Akita,et al.  Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. , 1993, Cancer research.

[186]  John Calvin Reed Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. , 1995, Current opinion in oncology.

[187]  A. Wyllie Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation , 1980, Nature.

[188]  A. Wyllie,et al.  Cell death: the significance of apoptosis. , 1980, International review of cytology.

[189]  B Angus,et al.  Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. , 1989, Cancer research.

[190]  K. Shin,et al.  Mutational analysis of promoters of mismatch repair genes hMSH2 and hMLH1 in hereditary nonpolyposis colorectal cancer and early onset colorectal cancer patients: identification of three novel germ-line mutations in promoter of the hMSH2 gene. , 2002, Cancer research.

[191]  M. Imamura,et al.  Hepatocyte growth factor: clinical implications in hepatobiliary pancreatic surgery. , 2001, Journal of hepato-biliary-pancreatic surgery.

[192]  R. Kerbel,et al.  Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. , 1995, Cancer research.

[193]  S. Thibodeau,et al.  hMLH1 and hMSH2 expression in human hepatocellular carcinoma. , 2001, International journal of oncology.

[194]  N. Bouck Angiogenesis: a mechanism by which oncogenes and tumor suppressor genes regulate tumorigenesis. , 1992, Cancer treatment and research.

[195]  Tatsuo Tanaka,et al.  Efficacy of an angiogenesis inhibitor, TNP‐470, in xenotransplanted human colorectal cancer with high metastatic potential , 1996, Cancer.

[196]  I. Schönborn,et al.  Significance of immunohistochemical c-erbB-2 product localization pattern for prognosis of primary human breast cancer. , 1994, Cancer letters.

[197]  J. Horiguchi,et al.  Immunohistochemical study on the expression of c-erbB-2 oncoprotein in breast cancer. , 1994, Oncology.

[198]  G. Breier,et al.  Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. , 1992, Development.

[199]  J. Lotem,et al.  Control of programmed cell death in normal and leukemic cells: new implications for therapy. , 1993, Blood.

[200]  T. Nose,et al.  Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. , 1996, Cancer research.

[201]  H. Kalthoff,et al.  Disseminated tumour cells. Their detection and significance for prognosis of gastrointestinal and pancreatic carcinomas. , 2001, Virchows Archiv : an international journal of pathology.

[202]  A. Harris,et al.  Mechanisms and therapeutic implications of angiogenesis. , 1996, Current opinion in oncology.

[203]  K. Plate Gene therapy of malignant glioma via inhibition of tumor angiogenesis , 1996, Cancer and Metastasis Reviews.

[204]  J. Cleveland,et al.  c-Myc and apoptosis. , 1995, Biochimica et biophysica acta.

[205]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[206]  D. Connolly,et al.  Vascular permeability factor, an endothelial cell mitogen related to PDGF. , 1989, Science.

[207]  K. Müller,et al.  Pathology of small-cell lung cancer , 2000, Journal of Cancer Research and Clinical Oncology.

[208]  J. W. Saunders,et al.  Death in Embryonic Systems , 1966, Science.

[209]  G. Tozer,et al.  Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. , 1997, Cancer research.

[210]  K. A. McKenna,et al.  p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32beta. , 1997, Cancer research.

[211]  A. Gazdar,et al.  Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. , 1996, Cancer research.

[212]  R. Eeles,et al.  The role of TP53 in breast cancer development. , 1993, Cancer surveys.

[213]  D. Clarke-Pearson,et al.  Overexpression of HER‐2/neu in endometrial cancer is associated with advanced stage disease , 1991, American journal of obstetrics and gynecology.

[214]  N. Copeland,et al.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis , 1992, Nature.

[215]  E. Abel Clinical applications of research on angiogenesis , 1996 .

[216]  J. Mountz,et al.  Abnormal thymocyte development and production of autoreactive T cells in T cell receptor transgenic autoimmune mice. , 1991, Journal of immunology.

[217]  J. Mountz,et al.  Defective maintenance of T cell tolerance to a superantigen in MRL- lpr/lpr mice , 1992, The Journal of experimental medicine.

[218]  R. D'Amato,et al.  Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. , 1997, Cancer research.

[219]  G. Evan,et al.  Apoptosis and the cell cycle. , 1995, Current opinion in cell biology.

[220]  J. Bartek,et al.  Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. , 1991, Oncogene.

[221]  W. Risau Embryonic angiogenesis factors. , 1991, Pharmacology & therapeutics.

[222]  N. Bertin,et al.  Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia. , 1997, Cancer research.

[223]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[224]  J. Bruner,et al.  Correlation of p53 immunoreactivity and sequencing in patients with glioma , 1996, Molecular carcinogenesis.

[225]  Goldman,et al.  Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. , 1993, Molecular biology of the cell.

[226]  R. Livingston,et al.  Chemotherapy and herceptin for HER2(+) metastatic breast cancer: the best drug? , 2001, The oncologist.

[227]  M. Greene,et al.  neu(c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. , 1993, Pathobiology : journal of immunopathology, molecular and cellular biology.

[228]  W. Blattner,et al.  Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome , 1990, Nature.

[229]  K. Kohn,et al.  Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. , 1995, Cancer research.

[230]  J. Mountz,et al.  Origin of CD4-CD8-B220+ T cells in MRL-lpr/lpr mice. Clues from a T cell receptor beta transgenic mouse. , 1993, Journal of immunology.

[231]  D. Schaid,et al.  Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[232]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.

[233]  N. Lemoine,et al.  The type 1 (EGFR-related) family of growth factor receptors and their ligands. , 1992, Progress in growth factor research.

[234]  Yosef Yarden,et al.  Isolation of the Neu HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells , 1992, Cell.

[235]  A. Chinnaiyan,et al.  ICE-LAP3, a Novel Mammalian Homologue of the Caenorhabditis elegans Cell Death Protein Ced-3 Is Activated during Fas- and Tumor Necrosis Factor-induced Apoptosis (*) , 1996, The Journal of Biological Chemistry.

[236]  Kuo-Fen Lee,et al.  Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.

[237]  M. Stoker Effect of scatter factor on motility of epithelial cells and fibroblasts , 1989, Journal of cellular physiology.

[238]  J. Jenkins,et al.  Mutant p53 proteins bind hsp 72/73 cellular heat shock-related proteins in SV40-transformed monkey cells. , 1987, Oncogene.

[239]  K. Kohn,et al.  p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. , 1994, Cancer research.

[240]  M. Steurer,et al.  Angiogenesis as a target for tumor treatment. , 1997, Oncology.

[241]  N. Jenkins,et al.  Generalized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand , 1994, Cell.

[242]  A. Wyllie,et al.  Apoptosis. The role of the endonuclease. , 1990, The American journal of pathology.

[243]  F. Waldman,et al.  ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. , 1995, Cancer research.

[244]  C. Obayashi,et al.  Thymoma: tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21 , 2004, Virchows Archiv.

[245]  Y. Lazebnik,et al.  Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE , 1994, Nature.

[246]  A. Wyllie,et al.  Hormone-induced cell death. 2. Surface changes in thymocytes undergoing apoptosis. , 1984, The American journal of pathology.

[247]  E. Alnemri,et al.  Mch2, a new member of the apoptotic Ced-3/Ice cysteine protease gene family. , 1995, Cancer research.

[248]  M. J. van de Vijver,et al.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.

[249]  H. M. Raup Drawings of British Plants, Being Illustrations of the Species of Flowering Plants Growing Naturally in the British Isles. Parts I-III: Ranunculaceae to Cruciferae.Stella Ross-Craig , 1951 .

[250]  D. Lowy,et al.  Function and regulation of ras. , 1993, Annual review of biochemistry.

[251]  Erwin G. Van Meir Hypoxia-mediated selection of cells with diminished apoptotic potential to solid tumours. , 1996, Neurosurgery.

[252]  E. Kremmer,et al.  Mapping of the Sites for Ligand Binding and Receptor Dimerization at the Extracellular Domain of the Vascular Endothelial Growth Factor Receptor FLT-1* , 1997, The Journal of Biological Chemistry.

[253]  Takashi Suda,et al.  Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor family , 1993, Cell.

[254]  F. Ramsdell,et al.  Fas transduces activation signals in normal human T lymphocytes , 1993, The Journal of experimental medicine.

[255]  J. Taylor‐Papadimitriou,et al.  Response to epidermal growth factors of cultured human mammary epithelial cells from benign tumours , 1976, Nature.

[256]  R. Lidereau,et al.  Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma. , 1988, Oncogene research.

[257]  R. Lupu,et al.  Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. , 1990, Science.

[258]  W. Chan,et al.  Apoptosis and Bcl‐2 oncoprotein expression in the human fetal central nervous system , 1998, The Anatomical record.

[259]  E. Gherardi,et al.  Regulation of cell movement: the motogenic cytokines. , 1991, Biochimica et biophysica acta.

[260]  L. Nanney,et al.  Increased epidermal growth factor receptors in seborrheic keratoses and acrochordons of patients with the dysplastic nevus syndrome. , 1990, Journal of the American Academy of Dermatology.

[261]  D. Lane,et al.  T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.

[262]  R. Kerbel,et al.  bFGF and tumor angiogenesis — Back in the limelight? , 1997, Nature Medicine.

[263]  T. Visakorpi,et al.  Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer , 1991, International journal of cancer.

[264]  D. Barnes c‐erbB‐2 amplification in mammary carcinoma , 1993, Journal of cellular biochemistry. Supplement.

[265]  L. Bardwell,et al.  Constitutive overexpression of a growth-regulated gene in transformed Chinese hamster and human cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[266]  M. Waterfield,et al.  Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system , 1993, Nature.

[267]  R. Odze,et al.  Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. , 2001, Human pathology.

[268]  C. Purdie,et al.  Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.

[269]  R. Fourney,et al.  Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. , 1991, Cancer research.

[270]  W. Fantl,et al.  Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. , 1995, Science.

[271]  R. Kimmig,et al.  Prognostic Relevance of hMLH1, hMSH2, and BAX Protein Expression in Endometrial Carcinoma , 2001, Modern Pathology.

[272]  T. Gansler,et al.  Evaluation of c-erbB-2 amplification in breast carcinoma by differential polymerase chain reaction. , 1994, American journal of clinical pathology.

[273]  M. Schemper,et al.  HER-2 oncogene amplification and overall survival of breast carcinoma patients. , 1990, European journal of cancer.

[274]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.

[275]  K. Plate,et al.  Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. , 1995, Cancer research.

[276]  N. Lemoine,et al.  The erbB‐3 Gene in human pancreatic cancer , 1992, The Journal of pathology.

[277]  H. Stein,et al.  Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease , 1992, Cell.

[278]  R. D'Amato,et al.  Inhibition of angiogenesis in vivo by interleukin 12. , 1995, Journal of the National Cancer Institute.

[279]  M. Cline,et al.  Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease. , 1989, Oncogene.

[280]  William Arbuthnot Sir Lane,et al.  ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family , 1993, Cell.

[281]  J. D. De Larco,et al.  Ectopic peptides released by a human melanoma cell line that modulate the transformed phenotype. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[282]  B. Angus,et al.  p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. , 1996, British Journal of Cancer.

[283]  A. Ullrich,et al.  Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences , 1984, Nature.

[284]  K. Arden,et al.  Mutation and expression of TP53 in malignant melanomas. , 1995, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[285]  R. Gelber,et al.  c-erbB-2 protein expression in node negative breast cancer. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[286]  A. Wyllie,et al.  Apoptosis: mechanisms and roles in pathology. , 1991, International review of experimental pathology.

[287]  A. van den Hooff,et al.  Stromal involvement in malignant growth. , 1988 .

[288]  H. Frierson,et al.  c-erbB-2 (HER-2/neu) oncopeptide immunoreactivity in localized, high-grade transitional cell carcinoma of the bladder. , 1992, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[289]  P. Krammer,et al.  Activation interferes with the APO-1 pathway in mature human T cells. , 1993, International immunology.

[290]  A. van den Hooff Stromal involvement in malignant growth. , 1988, Advances in cancer research.

[291]  A. Gottlieb,et al.  Detection of transforming growth factor alpha in normal, malignant, and hyperproliferative human keratinocytes , 1988, The Journal of experimental medicine.

[292]  W. J. Brammar,et al.  Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. , 1987, Oncogene.

[293]  S. Yonehara,et al.  A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor , 1989, The Journal of experimental medicine.

[294]  E. Tabor Tumor suppressor genes, growth factor genes, and oncogenes in hepatitis B virus‐associated hepatocellular carcinoma , 1994, Journal of medical virology.

[295]  S. Fox,et al.  TUMOUR ANGIOGENESIS , 1996, The Journal of pathology.

[296]  R. Elledge,et al.  The p53 tumor suppressor gene in breast cancer , 2004, Breast Cancer Research and Treatment.

[297]  Erwin G. Van Meir,et al.  Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells , 1994, Nature Genetics.

[298]  S. Korsmeyer Bcl-2: a repressor of lymphocyte death. , 1992, Immunology today.

[299]  Thierry Soussi,et al.  TP53 tumor suppressor gene: A model for investigating human mutagenesis , 1992, Genes, chromosomes & cancer.

[300]  S. Cohen,et al.  Epidermal growth factor , 1972, The Journal of investigative dermatology.

[301]  R. Abe,et al.  Immunohistochemical overexpression of C-erbB-2 in the prognosis of breast cancer , 2004, Surgery Today.

[302]  Y. Yoshihama,et al.  Prognostic significance of ERBB3 overexpression in oral squamous cell carcinoma. , 1995, Cancer letters.

[303]  D. Barnes,et al.  Expression of the ERBB3 gene product in breast cancer. , 1992, British Journal of Cancer.

[304]  G. Viale,et al.  Erratum: The fibronectin isoform containing the ED-B oncofetal domain: A marker of angiogenesis (Int. J. Cancer, 59, 612-618 (1994)) , 1995 .

[305]  B. Hoffman,et al.  Molecular controls of apoptosis: differentiation/growth arrest primary response genes, proto-oncogenes, and tumor suppressor genes as positive & negative modulators. , 1994, Oncogene.

[306]  K. Kondo,et al.  A dose‐response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients , 1996, Journal of surgical oncology.

[307]  W. Risau,et al.  Changes in the vascular extracellular matrix during embryonic vasculogenesis and angiogenesis. , 1988, Developmental biology.

[308]  D. Berry,et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.

[309]  L. Zardi,et al.  The fibronectin isoform containing the ed‐b oncofetal domain: A marker of angiogenesis , 1994, International journal of cancer.

[310]  H. P. Fell,et al.  Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions. , 1993, Journal of immunology.

[311]  C. Taylor Quality assurance and standardization in immunohistochemistry. A proposal for the annual meeting of the Biological Stain Commission, June, 1991. , 1992, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

[312]  S. Nagata,et al.  Lethal effect of the anti-Fas antibody in mice , 1993, Nature.

[313]  E. Gherardi,et al.  Scatter factor and other regulators of cell mobility. , 1989, British medical bulletin.

[314]  Q. Dou,et al.  Activation of cyclin E-dependent kinase by DNA-damage signals during apoptosis. , 1995, Biochemical and biophysical research communications.

[315]  J. Cohen,et al.  Endogenous endonuclease-induced DNA fragmentation: an early event in cell-mediated cytolysis. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[316]  W. Risau,et al.  Molecular biology of blood-brain barrier ontogenesis and function. , 1994, Acta neurochirurgica. Supplementum.

[317]  C. Marshall Tumor suppressor genes , 1991, Cell.

[318]  R. Coombes,et al.  Growth factor expression in Breast tissue , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[319]  R. Koski,et al.  Neu differentiation factor: A transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit , 1992, Cell.

[320]  P. Möller,et al.  Monoclonal antibody-mediated tumor regression by induction of apoptosis. , 1989, Science.

[321]  L. Cantley,et al.  The erbB3 gene product is a receptor for heregulin. , 1994, The Journal of biological chemistry.

[322]  F Pozza,et al.  Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. , 1992, Journal of the National Cancer Institute.

[323]  W. Clark,et al.  Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. , 1985, The New England journal of medicine.

[324]  G. Nicolson,et al.  c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. , 1994, Cancer research.

[325]  Y. Yoshihama,et al.  Prognostic significance of ERRB3 overexpression in oral squamous cell carcinoma , 1995 .

[326]  A. Klein-Szanto,et al.  Immunohistochemical Detection of c-erbB-2 Expression by Neoplastic Human Tissue using Monospecific and Bispecific Monoclonal Antibodies , 1993, The International journal of biological markers.

[327]  K. Schulze-Osthoff The Fas/APO-1 receptor and its deadly ligand. , 1994, Trends in cell biology.

[328]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[329]  J. E. Boers,et al.  P53 in squamous metaplasia: a marker for risk of respiratory tract carcinoma. , 1996, American journal of respiratory and critical care medicine.

[330]  A. Harris,et al.  Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer. , 1997, Cancer research.

[331]  S. Fan,et al.  Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. , 2001, American journal of clinical pathology.

[332]  T. Vu,et al.  Increased Expression of the Insulin-like Growth Factor-II Gene in Wilms' Tumor Is Not Dependent on Loss of Genomic Imprinting or Loss of Heterozygosity* , 1996, The Journal of Biological Chemistry.

[333]  D. Amadori,et al.  Base transitions are the most frequent genetic changes at P53 in gastric cancer. , 1993, Cancer research.

[334]  S. Molineaux,et al.  Molecular Cloning and Pro-apoptotic Activity of ICErelII and ICErelIII, Members of the ICE/CED-3 Family of Cysteine Proteases (*) , 1995, The Journal of Biological Chemistry.

[335]  Y. Yarden,et al.  Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. , 1996, The EMBO journal.

[336]  J. Varley,et al.  An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. , 1989, British Journal of Cancer.

[337]  L. Williams,et al.  Binding of NCK to SOS and activation of ras-dependent gene expression , 1995, Molecular and cellular biology.

[338]  J. Cairncross,et al.  Cell surface antigens of human astrocytoma defined by mouse monoclonal antibodies: identification of astrocytoma subsets. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[339]  J. M. Lee,et al.  p53 mutations increase resistance to ionizing radiation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[340]  D. Aust,et al.  Sixteen rare sequence variants of the hMLH1 and hMSH2 genes found in a cohort of 254 suspected HNPCC (hereditary non-polyposis colorectal cancer) patients: mutations or polymorphisms? , 2001, European journal of medical research.

[341]  G. Deng,et al.  Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression , 2001, Oncogene.

[342]  P. Heikkilä,et al.  Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[343]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[344]  I. Ellis,et al.  Production and characterization of a polyclonal antibody to the c‐erbB‐3 protein: Examination of c‐erbB‐3 protein expression in adenocarcinomas , 1992, The Journal of pathology.

[345]  M. Nair,et al.  Spontaneous programmed cell death in infiltrating duct carcinoma: association with p53, BCL-2, hormone receptors and tumor proliferation. , 1998, Pathology, research and practice.

[346]  Atsushi Hase,et al.  The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis , 1991, Cell.

[347]  W. Symmans,et al.  Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions. , 1995, Human pathology.

[348]  J. Goldblum,et al.  Hepatitis B and Alterations of the p53 Tumor Suppressor Gene in Hepatocellular Carcinoma , 1993, The American journal of surgical pathology.

[349]  K. Welte,et al.  Immunolocalization of granulocyte‐colony‐stimulating factor in human glial and primitive neuroectodermal tumors , 1994, International journal of cancer.

[350]  S. Fushida,et al.  Amplification of the c-erbB-2 gene in gastric carcinoma: correlation with survival. , 1993, Oncology.

[351]  S. Coleman,et al.  Ductal morphogenesis in the mouse mammary gland: evidence supporting a role for epidermal growth factor. , 1988, Developmental biology.

[352]  H. Engelhard,et al.  Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. , 1994, Cancer research.

[353]  P. Friedman,et al.  Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[354]  R. Kerbel,et al.  Oncogenes as inducers of tumor angiogenesis , 1995, Cancer and Metastasis Reviews.

[355]  W. McGuire,et al.  Follow-up study of HER-2/neu amplification in primary breast cancer. , 1991, Cancer research.

[356]  S. Nagata,et al.  Purification and characterization of the Fas-ligand that induces apoptosis , 1994, The Journal of experimental medicine.

[357]  H. Radzun,et al.  Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal cell carcinomas , 2001, Virchows Archiv.

[358]  G. Gores,et al.  The role of proteases during apoptosis , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[359]  A. Levine,et al.  Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells , 1982, Cell.

[360]  S. Donnini,et al.  An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. , 1997, Cancer research.

[361]  Scott W. Lowe,et al.  p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.

[362]  B. Davidson,et al.  The expression of antiapoptotic proteins Bcl-2, Bcl-X(L), and Mcl-1 in benign, dysplastic, and malignant biliary epithelium. , 2001, Journal of clinical pathology.

[363]  A GLUCKSMANN,et al.  Cell deaths in normal vertebrate ontogeny. , 1951, Biological reviews of the Cambridge Philosophical Society.

[364]  G. Fontanini,et al.  Receptor Status, Proliferating Activity, and c‐erbB2 Oncoprotein , 1993, Annals of the New York Academy of Sciences.

[365]  W. Gullick,et al.  A monoclonal antibody to the human c-erbB3 protein stimulates the anchorage-independent growth of breast cancer cell lines. , 1994, British Journal of Cancer.

[366]  R. Goody,et al.  Biochemical properties of Ha-ras encoded p21 mutants and mechanism of the autophosphorylation reaction. , 1988, The Journal of biological chemistry.

[367]  O. Melnyk,et al.  Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. , 1996, Cancer research.

[368]  A. Levine,et al.  Association of human papillomavirus types 16 and 18 E6 proteins with p53. , 1990, Science.

[369]  D. Horsfall,et al.  The significance of oncogene amplification in primary breast cancer , 1989, International journal of cancer.

[370]  N. Lemoine,et al.  Expression of the C‐erbB‐3 protein in gastrointestinal tract tumours determined by monoclonal antibody RTJ1 , 1993, The Journal of pathology.

[371]  L. Demers,et al.  Serial serum c‐erbB‐2 levels in patients with breast carcinoma , 1996, Cancer.

[372]  M. Sporn,et al.  Transforming growth factor beta. , 1988, Advances in cancer research.

[373]  Carmen Birchmeier,et al.  Multiple essential functions of neuregulin in development , 1995, Nature.

[374]  J. Cidlowski,et al.  Cell cycle and apoptosis: Common pathways to life and death , 1995, Journal of cellular biochemistry.

[375]  B. Gusterson,et al.  Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[376]  Akira Yamauchi,et al.  The intratumoral expression of vascular endothelial growth factor and interleukin‐8 associated with angiogenesis in nonsmall cell lung carcinoma patients , 2001, Cancer.

[377]  D. Slamon,et al.  Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. , 1994, Cancer research.

[378]  A. Harris p53 expression in human breast cancer. , 1992, Advances in cancer research.

[379]  T. Isobe,et al.  Epiregulin , 1995, The Journal of Biological Chemistry.

[380]  B. Bodey,et al.  Immunocytochemical observation of multidrug resistance (MDR) p170 glycoprotein expression in human osteosarcoma cells. The clinical significance of MDR protein overexpression. , 1995, Anticancer research.

[381]  A. Harris,et al.  c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. , 1991, British Journal of Cancer.

[382]  D. Goeddel,et al.  Identification of Heregulin, a Specific Activator of p185erbB2 , 1992, Science.